- Home
- ACIU vs VRXA Comparison
ACIU vs VRXA Comparison
Compare ACIU & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | VRXA |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Switzerland | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 263.0M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ACIU | VRXA |
|---|---|---|
| Price | $2.76 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 194.4K | ★ 380.8K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $706.75 | N/A |
| Revenue Next Year | $321.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $1.27 |
| 52 Week High | $4.00 | $4.50 |
Technical Indicators
Market Signals| Indicator | ACIU | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 44.64 |
| Support Level | $2.57 | $1.27 |
| Resistance Level | $3.00 | $1.99 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 27.38 | 52.05 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.